|12:0013:00||Stephen Friend, MD, Ph.D. , President of Sage Bionetworks|
Sage Bionetworks (Non-Profit Organization) Seattle/ Beijing, Sage Bionetworks EU Amsterdam
Title of his talk: Integrating layers of omics data models and compute spaces needed to build a Convivial Knowledge Expert
|14:0015:00||Carlos Caldas, Ph.D., Professor|
Breast Cancer Functional Genomics Laboratory, Cancer Research UK, Cambridge Research Institute
Title of his talk: A new molecular classification of breast cancer
Venue: New Research Building, Montebello. Open for all.
About the speakers:
Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Mercks Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited to join the Fred Hutchinson Cancer Research Centers Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
Professor Carlos Caldas has held the Chair of Cancer Medicine at the University of Cambridge since 2002. He heads the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Research Institute. He is an Honorary Consultant Medical Oncologist at Addenbrookes Hospital, Lead of the Cambridge Experimental Cancer Medicine Centre and Director of the Cambridge Breast Cancer Research Unit which opened at Addenbrookes Hospital last year. He is Fellow of the American College of Physicians, the Royal College of Physicians and the Royal College of Pathologists. He was elected a Fellow of the Academy of the Medical Sciences in 2004.His current research focus is in the functional genomics of breast cancer and its biological and clinical implications. His main clinical interest is in breast cancer chemotherapy and novel molecularly targeted therapies.
Host of the meeting: Anne-Lise Børresen-Dale, Professor, Head of Department of Genetics